These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22458682)

  • 21. Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.
    Dousson CB
    Antivir Chem Chemother; 2018; 26():2040206618756430. PubMed ID: 29463095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
    Beaulieu PL
    IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Wu JZ; Yao N; Walker M; Hong Z
    Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Koch U; Narjes F
    Curr Top Med Chem; 2007; 7(13):1302-29. PubMed ID: 17627559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleotide prodrugs for the treatment of HCV infection.
    Sofia MJ
    Adv Pharmacol; 2013; 67():39-73. PubMed ID: 23885998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Expert Opin Pharmacother; 2013 Jun; 14(9):1161-70. PubMed ID: 23621117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication.
    Nilsson M; Kalayanov G; Winqvist A; Pinho P; Sund C; Zhou XX; Wähling H; Belfrage AK; Pelcman M; Agback T; Benckestock K; Wikström K; Boothee M; Lindqvist A; Rydegård C; Jonckers TH; Vandyck K; Raboisson P; Lin TI; Lachau-Durand S; de Kock H; Smith DB; Martin JA; Klumpp K; Simmen K; Vrang L; Terelius Y; Samuelsson B; Rosenquist S; Johansson NG
    Bioorg Med Chem Lett; 2012 May; 22(9):3265-8. PubMed ID: 22472694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase.
    Koch U; Narjes F
    Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.
    Rondla R; Coats SJ; McBrayer TR; Grier J; Johns M; Tharnish PM; Whitaker T; Zhou L; Schinazi RF
    Antivir Chem Chemother; 2009 Oct; 20(2):99-106. PubMed ID: 19843980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Non-hydrolysable analogs of inorganic pyrophosphate as inhibitors of hepatitis C virus RNA-dependent RNA-polymerase].
    Ianvarev DV; Korovina AN; Usanov NN; Kochetkov SN
    Bioorg Khim; 2012; 38(2):257-62. PubMed ID: 22792731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
    Chun BK; Du J; Zhang HR; Chang W; Ross BS; Jiang Y; Bao D; Espiritu CL; Keilman M; Steuer HM; Furman PA; Sofia MJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):886-96. PubMed ID: 22060553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and anti-HCV activity of a new 2'-deoxy-2'-fluoro-2'-C-methyl nucleoside analogue.
    Hu W; Wang P; Song C; Pan Z; Wang Q; Guo X; Yu X; Shen Z; Wang S; Chang J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7297-8. PubMed ID: 21106452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.
    Carroll SS; Ludmerer S; Handt L; Koeplinger K; Zhang NR; Graham D; Davies ME; MacCoss M; Hazuda D; Olsen DB
    Antimicrob Agents Chemother; 2009 Mar; 53(3):926-34. PubMed ID: 19075052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.
    Jonckers TH; Vandyck K; Vandekerckhove L; Hu L; Tahri A; Van Hoof S; Lin TI; Vijgen L; Berke JM; Lachau-Durand S; Stoops B; Leclercq L; Fanning G; Samuelsson B; Nilsson M; Rosenquist Å; Simmen K; Raboisson P
    J Med Chem; 2014 Mar; 57(5):1836-44. PubMed ID: 24345201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase.
    Di Francesco ME; Avolio S; Pompei M; Pesci S; Monteagudo E; Pucci V; Giuliano C; Fiore F; Rowley M; Summa V
    Bioorg Med Chem; 2012 Aug; 20(15):4801-11. PubMed ID: 22770556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico design of a novel nucleotide antiviral agent by free energy perturbation.
    Patel D; Cox BD; Kasthuri M; Mengshetti S; Bassit L; Verma K; Ollinger-Russell O; Amblard F; Schinazi RF
    Chem Biol Drug Des; 2022 Jun; 99(6):801-815. PubMed ID: 35313085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
    Brown JA; Thorpe IF
    Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.